Biocartis, BioMérieux End MDx Alliance | GenomeWeb

NEW YORK (GenomeWeb News) – Biocartis and BioMérieux on Thursday announced a mutual agreement to end their alliance to develop and commercialize the integrated molecular biology system called Idylla.

All rights to the platform, formerly called Apollo and developed by Biocartis in collaboration with Philips Corporate Technologies, will be returned to Biocartis, which will have all rights to Idylla now related to its use in the microbiology field, Biocartis said. The company also is free to explore new strategic options for the platform in the microbiology field, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.